PL393611A1 - Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków - Google Patents

Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków

Info

Publication number
PL393611A1
PL393611A1 PL393611A PL39361199A PL393611A1 PL 393611 A1 PL393611 A1 PL 393611A1 PL 393611 A PL393611 A PL 393611A PL 39361199 A PL39361199 A PL 39361199A PL 393611 A1 PL393611 A1 PL 393611A1
Authority
PL
Poland
Prior art keywords
compounds
analogues
glp
compositions containing
peptide
Prior art date
Application number
PL393611A
Other languages
English (en)
Inventor
Zheng Xin Dong
David H. Coy
Original Assignee
Societe De Conseils De Recherches Et D'applications Scientifiques Sas
The Administrators Of The Tulane Educational Fund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe De Conseils De Recherches Et D'applications Scientifiques Sas, The Administrators Of The Tulane Educational Fund filed Critical Societe De Conseils De Recherches Et D'applications Scientifiques Sas
Publication of PL393611A1 publication Critical patent/PL393611A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
PL393611A 1998-12-07 1999-12-07 Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków PL393611A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11118698P 1998-12-07 1998-12-07
US20683398A 1998-12-07 1998-12-07

Publications (1)

Publication Number Publication Date
PL393611A1 true PL393611A1 (pl) 2011-05-09

Family

ID=26808707

Family Applications (3)

Application Number Title Priority Date Filing Date
PL349609A PL205713B1 (pl) 1998-12-07 1999-12-07 Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
PL385112A PL208751B1 (pl) 1998-12-07 1999-12-07 Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków
PL393611A PL393611A1 (pl) 1998-12-07 1999-12-07 Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL349609A PL205713B1 (pl) 1998-12-07 1999-12-07 Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
PL385112A PL208751B1 (pl) 1998-12-07 1999-12-07 Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków

Country Status (21)

Country Link
US (2) US7368427B1 (pl)
EP (2) EP1137666B9 (pl)
JP (3) JP2002538081A (pl)
KR (1) KR100458748B1 (pl)
CN (2) CN100334109C (pl)
AT (1) ATE394423T1 (pl)
AU (1) AU770609B2 (pl)
BR (1) BR9916027A (pl)
CA (1) CA2352573C (pl)
CZ (2) CZ303120B6 (pl)
DE (1) DE69938669D1 (pl)
DK (1) DK1137666T5 (pl)
ES (1) ES2302390T3 (pl)
HU (1) HUP0104579A3 (pl)
IL (2) IL143481A0 (pl)
NO (2) NO330293B1 (pl)
PL (3) PL205713B1 (pl)
PT (1) PT1137666E (pl)
RU (1) RU2208015C2 (pl)
TW (2) TWI262925B (pl)
WO (1) WO2000034332A1 (pl)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322545A1 (en) 1998-12-07 2011-05-18 Ipsen Pharma Analogues of GLP-1
KR100458748B1 (ko) * 1998-12-07 2004-12-03 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 Ｇｌｐ-1 유사체
JP2004509079A (ja) * 2000-08-02 2004-03-25 セラテクノロジーズ・インコーポレーテッド 効力が増大した修飾生体ペプチド
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
EP1326630B1 (en) 2000-09-18 2008-05-28 Sanos Bioscience A/S Use of glp-2 peptides
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US6894024B2 (en) * 2000-10-20 2005-05-17 Amylin Pharmaceuticals, Inc. Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
EP1346722B1 (en) 2000-12-01 2008-12-10 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive substance
EP2022505B1 (en) * 2001-07-31 2011-12-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
AU2012202081B2 (en) * 2001-07-31 2014-09-25 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 Exendin-4 peptide analogs and uses thereof
JP2005514337A (ja) * 2001-10-18 2005-05-19 ブリストル−マイヤーズ　スクイブ　カンパニー ヒトグルカゴン様ペプチド−１模倣体、並びに糖尿病および関連疾患の処置におけるその使用
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
WO2004009616A2 (en) * 2002-07-23 2004-01-29 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Ghrelin analogs
EP1583549A4 (en) * 2003-01-17 2006-10-04 Sod Conseils Rech Applic YY PEPTIDE ANALOGS
DE602004025205D1 (de) * 2003-02-19 2010-03-11 Ipsen Pharma Glp-1-analoga
JP4543236B2 (ja) * 2003-03-28 2010-09-15 独立行政法人農業生物資源研究所 組換えタンパク質が高生産された植物貯蔵器官の生産方法及び新規組換えタンパク質
US7094800B2 (en) 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
US7008957B2 (en) 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7094794B2 (en) 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (de) 2003-08-01 2005-02-03 Aventis Pharma Deutschland Gmbh Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
EP2210900A3 (en) * 2003-12-16 2010-08-11 Ipsen Pharma Analogues of GLP-1
TWI353250B (en) * 2003-12-16 2011-12-01 Ipsen Pharma Sas Glp-1 pharmaceutical compositions
AU2005203925A1 (en) 2004-01-08 2005-07-21 Theratechnologies Inc. Glucagon-Like Peptide-1 analogs with long duration of action
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
JP2008543816A (ja) * 2005-06-13 2008-12-04 インペリアル イノベーションズ リミテッド 新規化合物および該化合物が摂食行動に及ぼす効果
WO2007051987A1 (en) * 2005-11-01 2007-05-10 Activotec Spp Limited Insulinotropic compounds and uses thereof
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
CA2648936C (en) 2006-04-20 2013-07-09 Amgen Inc. Glp-1 compounds
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
US8669228B2 (en) * 2007-01-05 2014-03-11 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
JP2010538069A (ja) * 2007-09-07 2010-12-09 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ エキセンディン−４およびエキセンディン−３の類似体
CN102088989B (zh) * 2008-06-17 2014-11-26 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
WO2010076809A2 (en) * 2008-12-29 2010-07-08 Panacea Biotec Ltd Glp-1 analogs and uses thereof
RU2580317C2 (ru) * 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
WO2012054861A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Glp-1 polymer conjugates having a releasable linkage
EP2713722B1 (en) 2011-05-31 2017-03-15 Receptos, LLC Novel glp-1 receptor stabilizers and modulators
KR20140107340A (ko) 2011-12-12 2014-09-04 레셉토스, 인코포레이티드 당뇨병과 같은 치료를 위한 glp-1 수용체 조절제로서 작용하는 4 개의 사이클을 포함하는 카르복실산 유도체
CN102584982B (zh) * 2012-02-10 2014-02-05 深圳翰宇药业股份有限公司 一种纯化固相合成利拉鲁肽粗肽的方法
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
SI3004155T1 (sl) 2013-05-28 2022-02-28 Takeda Pharmaceutical Company Limited Peptidna spojina
CN103285379A (zh) * 2013-06-09 2013-09-11 南方医科大学 Glp-1用于制备预防与治疗2型糖尿病大血管并发症的药物的用途
EP3008056B8 (en) 2013-06-11 2021-03-03 Receptos Llc Novel glp-1 receptor modulators
CA2955836C (en) 2014-07-25 2023-02-14 Celgene International Ii Sarl Glp-1 receptor modulators
JP2018012644A (ja) * 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物
CA2969944A1 (en) 2014-12-10 2016-06-16 Celgene International Ii Sarl Glp-1 receptor modulators
BR112017019170A2 (pt) 2015-03-09 2018-07-10 Intekrin Therapeutics, Inc. métodos para o tratamento de doença do fígado gorduroso não alcoólico e / ou lipodistrofia
SG11201805255TA (en) 2015-12-23 2018-07-30 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
AU2016379403B2 (en) 2015-12-23 2020-03-12 The Johns Hopkins University Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
JP6995042B2 (ja) 2016-05-24 2022-02-04 武田薬品工業株式会社 ペプチド化合物
JP2019520336A (ja) 2016-06-02 2019-07-18 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 水溶性で化学的に安定なグルカゴンペプチド
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
CN109942696A (zh) * 2017-12-21 2019-06-28 中国药科大学 长效化胰高血糖素样肽－1（glp－1）类似物及其应用
CN116970062B (zh) * 2022-04-29 2024-04-09 南京知和医药科技有限公司 一种超长效glp-1多肽衍生物及其制备方法和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1539498A (en) 1925-05-26 And fifteen
CA2073856C (en) * 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
JP2575298B2 (ja) * 1992-06-15 1997-01-22 フアイザー・インコーポレイテツド グルカゴン様ペプチド及びインシュリノトロピン誘導体
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
EP0879279A4 (en) * 1996-02-06 2000-07-12 Lilly Co Eli DIABETE TREATMENT
DE69737479T4 (de) * 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
WO1998043658A1 (en) * 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
EP1056774A1 (en) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
KR100458748B1 (ko) 1998-12-07 2004-12-03 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 Ｇｌｐ-1 유사체
EP2322545A1 (en) 1998-12-07 2011-05-18 Ipsen Pharma Analogues of GLP-1
WO2001035988A1 (en) 1999-11-12 2001-05-25 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration

Also Published As

Publication number Publication date
TWI262925B (en) 2006-10-01
DK1137666T3 (da) 2008-09-08
BR9916027A (pt) 2001-08-28
ATE394423T1 (de) 2008-05-15
HUP0104579A3 (en) 2002-05-28
PL205713B1 (pl) 2010-05-31
CA2352573A1 (en) 2000-06-15
AU1751200A (en) 2000-06-26
TW200628489A (en) 2006-08-16
JP2002538081A (ja) 2002-11-12
EP1137666B9 (en) 2009-04-01
JP2006077022A (ja) 2006-03-23
IL143481A0 (en) 2002-04-21
NO20012787L (no) 2001-08-06
EP1137666B1 (en) 2008-05-07
CA2352573C (en) 2012-04-10
AU770609B2 (en) 2004-02-26
EP1992641A3 (en) 2009-07-29
NO20100307L (no) 2001-08-06
EP1137666A1 (en) 2001-10-04
US7368427B1 (en) 2008-05-06
KR100458748B1 (ko) 2004-12-03
CN100334109C (zh) 2007-08-29
CN101108878A (zh) 2008-01-23
JP2010001301A (ja) 2010-01-07
DK1137666T5 (da) 2009-10-05
HUP0104579A2 (hu) 2002-04-29
WO2000034332A1 (en) 2000-06-15
IL143481A (en) 2010-02-17
US20090149378A1 (en) 2009-06-11
EP1992641A2 (en) 2008-11-19
CN1342166A (zh) 2002-03-27
CN101108878B (zh) 2012-08-29
DE69938669D1 (de) 2008-06-19
CZ20011895A3 (cs) 2001-12-12
ES2302390T3 (es) 2008-07-01
NO330293B1 (no) 2011-03-21
CZ303399B6 (cs) 2012-08-29
KR20010102953A (ko) 2001-11-17
CZ303120B6 (cs) 2012-04-11
TWI339208B (en) 2011-03-21
PL208751B1 (pl) 2011-06-30
NO20012787D0 (no) 2001-06-06
PT1137666E (pt) 2008-06-02
RU2208015C2 (ru) 2003-07-10

Similar Documents

Publication Publication Date Title
PL393611A1 (pl) Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków
HK1037196A1 (en) Analogues of glp-1.
MXPA02012203A (es) Analogos de peptido 1 tipo glucagon.
WO2005058252A3 (en) Glp-1 pharmaceutical compositions
WO2004074315A3 (en) Analogues of glp-1
UA35636C2 (uk) Поліпептид, який має активність легеневої поверхнево-активної речовини, та фармацевтична композиція для лікування респіраторного дистрес-синдрому у ссавців
IL128740A0 (en) Use of glucagon-like peptide-1 (glp-1) or analogs to abolish catabolic changes after surgery
CO5090908A1 (es) Procedimiento para administrar peptidos insulinotropicos
YU41199A (sh) Hinoksalindioni
UA41355C2 (uk) Засіб для лікування нейро-сніду
MX2008001468A (es) Composiciones farmaceuticas del peptido similar al glucagon-1.
DE59308848D1 (de) Anwendung von urodilatin bei lungen- und bronchialerkrankungen
EP2210900A3 (en) Analogues of GLP-1
EP1359159A3 (en) Analogues of GLP-1
YU40398A (sh) Kompozicija nazalnog spreja za davanje sredstva za lečenje odloženog napada emezisa
ATE282608T1 (de) Chinoxalindionen
UA88862C2 (en) Glucagon-like peptide-1 analogs

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)